aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Krystal Biotech is a Pennsylvania-based biopharmaceutical company focused on developing and delivering genetic medicines for severe, life-threatening, or rare diseases with limited or no approved therapies. Utilizing a proprietary gene therapy platform, Krystal Biotech aims to address high unmet medical needs with redosable gene therapies. Their first commercial product, VYJUVEK®, is the only redosable gene therapy for treating dystrophic epidermolysis bullosa.
Krystal Biotech has made significant strides in the biopharmaceutical industry, particularly with the launch of VYJUVEK®, marking a milestone in gene therapy for rare disorders. The company's innovative approach and dedication to addressing unmet medical needs have positioned it as a leader in genetic medicine. Their extensive and promising pipeline continues to advance, reflecting their commitment to transforming the lives of patients with debilitating conditions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Gene Therapy
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Krystal Biotech founded?
Krystal Biotech was founded in 2017.
Where is Krystal Biotech’s headquarters located?
Krystal Biotech’s headquarters is located in Pittsburgh, PA, US.
When was Krystal Biotech’s last funding round?
Krystal Biotech’s most recent funding round was for $160M (USD) in May 2023.
How many employees does Krystal Biotech have?
Krystal Biotech has 210 employees as of Feb 6, 2024.
How much has Krystal Biotech raised to-date?
As of July 05, 2023, Krystal Biotech has raised a total of $546M (USD) since May 21, 2023.
Add Comparison
Total Raised to Date
$546M
USD
Last Update May 21, 2023
Last Deal Details
$160M
USD
May 21, 2023
Post Ipo Equity
Total Employees Over Time
210
As of Feb 2024
Krystal Biotech Address
2100 Wharton St.
# 701
Pittsburgh,
Pennsylvania
15203
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts